Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 38 - Medicinal preparations containing peptides
Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
11/2003
11/13/2003WO2003092579A2 Compositions and methods for treating cancer with an oncolytic viral agent
11/13/2003WO2003092475A2 Diagnosis and treatment of glaucoma
11/13/2003WO2003092474A2 Vascularization enhanced graft constructs
11/13/2003WO2003092468A2 Biomatrix structural containment and fixation systems and methods of use thereof
11/13/2003WO2003080654A3 Helicobacter flagellar, motility polypeptides
11/13/2003WO2003076621A3 Vpr modulators and uses thereof
11/13/2003WO2003068968A3 Mutated gene coding for a lat protein and the biological applications thereof
11/13/2003WO2003066680A3 Antigens for immunocontraception
11/13/2003WO2003064614A3 Transport peptides and uses therefor
11/13/2003WO2003064587A3 Hif-1 alpha proteins mutated in the c-terminal transactivation domain
11/13/2003WO2003064447A3 Immune-modulating peptide
11/13/2003WO2003061680A3 Use of compounds having the biological activity of vasoactive intestinal peptide for the treatment of chronic obstructive pulmonary disease
11/13/2003WO2003060143A3 Efficient protein expression system
11/13/2003WO2003052067A3 Vector mediated organelle transfection
11/13/2003WO2003048190A3 Acyclovir-peptide analogs
11/13/2003WO2003047526A3 Cell adhesion and extracellular matrix proteins
11/13/2003WO2003045976A3 Use of antimicrobial proteins and peptides for the treatment of otitis media and paranasal sinusitis
11/13/2003WO2003045225A3 Composition and method for treating the over-production of mucin in diseases such as otitis media using an inhibitor of muc5ac
11/13/2003WO2003040691A3 Soluble cd40l(cd154) as a prognostic marker of atherosclerotic diseases
11/13/2003WO2003039444A3 Topical use of cytokines and/or chemokines for the treatment of viral or mykotic skin diseases or tumoral diseases
11/13/2003WO2003034985A3 Telomerase interference
11/13/2003WO2003034938A3 Vascular stent or graft coated or impregnated with protein tyrosine kinase inhibitors and method of using same
11/13/2003WO2003033653A3 Affinity enhancement agents
11/13/2003WO2003031942A8 Reagents and methods useful for detecting diseases of the breast
11/13/2003WO2003031621A3 A human g protein coupled receptor
11/13/2003WO2003031459A3 Modulation of the expression of genes dependent on stat-1
11/13/2003WO2003030944A3 Inhibition of stat-1
11/13/2003WO2003029436A3 Ul16 binding protein 4
11/13/2003WO2003028657A9 Compositions for oral gene therapy and methods of using same
11/13/2003WO2003028536A3 Methods for diagnosing and treating heart disease
11/13/2003WO2003027316A3 Methods of using 33751, a human potassium channel family member
11/13/2003WO2003023003A3 Nucleic acid-associated proteins
11/13/2003WO2003022871A3 Peptides having a c- terminal hydroxylamino group as inhibitors of dipeptidyl peptidase i
11/13/2003WO2003022806A3 Cbi analogues of cc-1065 and the duocarmycins
11/13/2003WO2003020262A3 Use of polyunsaturated fatty acids for intra-arterial injection for selectively occluding blood supplies to neoplasias
11/13/2003WO2003018134A3 Bioadhesive compositions and methods for enhanced mucosal drug absorption
11/13/2003WO2003018059A3 Combination preparations of aryl substituted propanolamine derivatives with other active ingredients and the use thereof
11/13/2003WO2003017917A3 Use of microbiology non-viral substances for treating acne
11/13/2003WO2003015615A3 Treatment of muscular dystrophies and related disorders
11/13/2003WO2003014157A3 Peptides conjugates, their derivatives with metal complexes and use thereof for magnetic resonance imaging (mri)
11/13/2003WO2003013432A3 Methods of use for novel sulfur containing organic nitrate compounds
11/13/2003WO2003012111A3 Conjugates for the modulation of immune responses
11/13/2003WO2003010281A3 Protein kinase inhibitors comprising atp mimetics conjugated to peptides or peptidomimetics
11/13/2003WO2003009778A3 Methods and devices for delivery of therapeutic capable agents with variable release profile
11/13/2003WO2003006657A3 Gene-regulatory elements for gene therapy, for the prevention and diagnosis of metastases and for the gene therapy of tumours
11/13/2003WO2003000918A3 Nucleic acids, polypeptides, single nucleotide polymorphisms and methods of use thereof
11/13/2003WO2003000227A3 A method for preparation of vesicles loaded with biological material and different uses thereof
11/13/2003WO2002102984A3 Hdac9 polypeptides and polynucleotides and uses thereof
11/13/2003WO2002099115A3 Nucleic acid-associated proteins
11/13/2003WO2002098443A3 Stabilised mrna with an increased g/c content and optimised codon for use in gene therapy
11/13/2003WO2002097074A3 Human protein phosphatase 2c-like enzyme
11/13/2003WO2002094250A3 Therapeutic uses of lna-modified oligonucleotides in infectious diseases
11/13/2003WO2002092831A3 Method for identifying ligands for g protein coupled receptors
11/13/2003WO2002079402A3 Method of inhibiting cancerous cell proliferation using ras mutants of gdp-bound conformation
11/13/2003WO2002079252A8 Isolated human transporter protein, nucleic acid molecules encoding human transporter protein, and uses thereof
11/13/2003WO2002079243A3 Gonococcal proteins and nucleic acids
11/13/2003WO2002077010A8 Method of preventing t-cell mediated responses by map proteins
11/13/2003WO2002074905A3 Leptin induced genes
11/13/2003WO2002072888A3 Polymorphisms in the human cmoat gene and uses thereof
11/13/2003WO2002072770A3 Novel human proteins, polynucleotides encoding them and methods of using the same
11/13/2003WO2002070538A3 Narc8 programmed cell-death-associated molecules and uses thereof
11/13/2003WO2002066681A3 Reagents and methods for identifying and modulating expression of genes regulated by cdk inhibitors
11/13/2003WO2002066648A3 Immunoglobulin superfamily variants expressed in mesenchymal cells and therapeutic uses thereof
11/13/2003WO2002064796A8 Butyrylcholinesterase polypeptide variants with increased catalytic efficiency and methods of use
11/13/2003WO2002057779A8 Cloning and expression of a new mcp receptor in glial cells
11/13/2003WO2002057302A8 A virus causing respiratory tract illness in susceptible mammals
11/13/2003WO2002057290A8 Novel fibronectin epitopes and proteinaceous molecules capable of binding said epitopes
11/13/2003WO2002048715A3 Inflammatory markers for detection and prevention of diabetes mellitus
11/13/2003WO2002048339A3 Transgenic mice containing kir5.1 inwardly rectifying potassium channel gene disruptions
11/13/2003WO2002032874A8 Substituted heterocyclic compounds for treating multidrug resistance
11/13/2003WO2002030443A9 Regulation of human skin healing
11/13/2003WO2002014362A3 A hepatitis c virus non-structural ns3/4a fusion gene
11/13/2003WO2002014348B1 Glycoproteins and methods of use thereof
11/13/2003WO2000021978A3 Laminin 5, 13 and 14 and uses thereof
11/13/2003US20030213004 Composition comprising ribozyme/monoclonal antibody fusion protein for treating cell proliferative disorders; anticarcinogenic/antiproliferative agents
11/13/2003US20030213003 Preparing and recoverng genetically engineered fusion protein for treating diabetes
11/13/2003US20030212266 Growth arrest homeobox gene
11/13/2003US20030212258 Comprises nucleotide sequences coding polypeptide for diagnosis, prevention and treatment of reproductive, inflammatory, nervous system and cancer disorders
11/13/2003US20030212256 Comprises a disintegrin and metalloprotease (ADAM) for use in prevention, diagnosis and treatment of cancer, cardiomyopathy and atherosclerosis
11/13/2003US20030212249 Synthesis of cyclosporin analogs
11/13/2003US20030212115 Remedies for inflammatory bowel diseases
11/13/2003US20030212088 Methods and compositions for treating, preventing or delaying onset of a neoplasm
11/13/2003US20030212067 Bone disorders; rheumatic diseases; wound healing agents
11/13/2003US20030212048 Pharmaceutical compositions comprising in combination a bisphosphonate and a matrix metalloproteinase inhibitor
11/13/2003US20030212030 Blood disorders; synergistic mixture of vector and monoclonal antibody
11/13/2003US20030212026 Induce immunology response
11/13/2003US20030212025 Cd154 variants
11/13/2003US20030212024 Compositions and methods for cell dedifferentiation and tissue regeneration
11/13/2003US20030212021 Myeloid colony stimulating factor and uses thereof
11/13/2003US20030212020 Antisense modulation of macrophage migration inhibitory factor expression
11/13/2003US20030212019 Hybrid nucleic acid; anticancer agents
11/13/2003US20030212016 Methods and compositions for the treatment and diagnosis of body weight disorders
11/13/2003US20030212015 Specific modulation of Th1/Th2 cytokine expression by ribavirin in activated T-lymphocytes
11/13/2003US20030212005 Hydrolyzed collagen mixture
11/13/2003US20030212004 Therapeutic use of aerosolized s-nitrosoglutathione in cystic fibrosis
11/13/2003US20030212003 Cathepsin Y for the development of a medicament for the treatment of pain
11/13/2003US20030212002 Peptide for controlling appetite
11/13/2003US20030212001 Methods and compounds for prevention and treatment of elevated intraocular pressure and related conditions
11/13/2003US20030212000 Immunoprotective methods for beta cell neogenesis
11/13/2003US20030211998 Brain disorders; cardiovascular disorders
1 ... 1732 1733 1734 1735 1736 1737 1738 1739 1740 1741 1742 1743 1744 1745 1746 1747 1748 1749 1750 1751 1752 ... 3163